Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells 346 Shares

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 346 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $87.32, for a total transaction of $30,212.72. Following the sale, the insider directly owned 119,346 shares in the company, valued at $10,421,292.72. This trade represents a 0.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Monday, June 8th, Dennis Cho sold 402 shares of Twist Bioscience stock. The shares were sold at an average price of $69.84, for a total transaction of $28,075.68.

Twist Bioscience Stock Performance

TWST traded up $6.35 on Wednesday, hitting $91.35. 2,440,610 shares of the company’s stock were exchanged, compared to its average volume of 1,477,205. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. The stock has a fifty day moving average of $64.56 and a two-hundred day moving average of $50.23. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $93.80. The firm has a market cap of $5.69 billion, a PE ratio of -68.68 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The company had revenue of $110.72 million for the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The firm’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period last year, the company posted ($0.66) earnings per share. On average, research analysts anticipate that Twist Bioscience Corporation will post -2.02 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Stifel Financial Corp raised its holdings in shares of Twist Bioscience by 3.6% during the fourth quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock valued at $246,000 after acquiring an additional 271 shares during the period. D.A. Davidson & CO. boosted its stake in Twist Bioscience by 1.2% in the 4th quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after purchasing an additional 305 shares during the period. CWM LLC grew its position in Twist Bioscience by 9.4% during the 4th quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after purchasing an additional 407 shares in the last quarter. California State Teachers Retirement System grew its position in Twist Bioscience by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after purchasing an additional 442 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after purchasing an additional 453 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on TWST shares. Barclays raised their target price on Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th. Canaccord Genuity Group began coverage on shares of Twist Bioscience in a research report on Monday, June 15th. They issued a “buy” rating and a $90.00 price objective on the stock. Piper Sandler initiated coverage on shares of Twist Bioscience in a research report on Thursday, June 11th. They issued an “overweight” rating and a $85.00 price objective on the stock. Finally, UBS Group set a $89.00 target price on shares of Twist Bioscience in a research note on Monday, June 15th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $74.60.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.